SUMMARY

[0005] Provided herein are compounds and methods useful for the treatment of various diseases, disorders, or conditions. In a first aspect, provided herein is a compound of Formula (**A**):



(**A**);

or a pharmaceutically acceptable salt, solvate, stereoisomer, or derivative thereof, wherein:

R^1 and R^2 are, independently, –H, alkyl, alkyl-C(O)-O–, –OH, or halo; or R^1 and R^2 together form ,

wherein R^4 is alkyl, aryl, arylalkyl, or an N-containing heterocycloalkyl, wherein the alkyl, aryl, arylalkyl, and N-containing heterocycloalkyl are, independently in each instance, optionally substituted with $-NR^aR^b$;

R^3 is –OH, R^Z-C(O)-X–, heteroalkyl, piperidinyl, $–NR^aR^b$, -oxyaryl–NR^aR^b or $-Z-A(R^P)_t$;

R^5 is, independently in each instance, –OH, halo, alkyl, or arylalkyl;

R^Z is alkyl;

X is O or NR^a;

Z is S, S(O), $S(O)_2$, SO_2NR^a, O, $C(O)NR^a$, C(O), or NR^a;

A is aryl, arylalkyl, or heteroaryl;

R^P is, independently in each instance, halo, optionally substituted alkyl, –OH, or $-NR^aR^b$;

R^a and R^b are, independently in each instance, –H, optionally substituted alkyl, or optionally subtitued aryl;

n is an integer from 0-19; and

t is an integer from 1-3;

with the proviso that:

(1) R^3 is not –OH (a) when R^1 is –OH or (b) when R^1 and R^2 together form ,

wherein R^4 is $C_{1\text{-}9}$alkyl or  and

(2) R^3 is not .

[0006] Provided herein are compounds that are protein-drug conjugates, *e.g.*, antibody-drug conjugates, comprising an antigen-binding protein, *e.g.*, antibody and a compound of Formula (**A**).

[0006a] In a second aspect, provided herein is a compound comprising a binding agent conjugated to a compound as defined herein.

[0007] Provided herein are compounds that are protein-drug conjugates, *e.g.*, antibody-drug conjugates, comprising an antigen-binding protein, *e.g.*, antibody, a compound of Formula (**A**), and a cyclodextrin moiety.

[0007a] In a third aspect, provided herein is a compound comprising a binding agent conjugated to a compound as defined herein and a cyclodextrin (**CD**).

[0007b] In a fourth aspect, provided herein is use of a compound as defined in the first aspect or a compound as defined in the second or the third aspect for treating a disease, disorder, or condition associated with glucocorticoid receptor signaling comprising administering to a patient having said disease, disorder, or condition.

[0007c] In a fifth aspect, provided herein is an *in vitro* method of delivering a compound as defined herein to a cell comprising contacting said cell with a protein steroid conjugate of said compound, wherein said protein conjugate comprises an antibody or antigen binding fragment thereof that binds a surface antigen of said cell.

[0007d] In a sixth aspect, provided herein is a linker-payload comprising the compound as defined herein linked to a reactive group, optionally via a linker.

BRIEF DESCRIPTIONS OF THE DRAWINGS

[0008] FIG. 1. shows a sequence for synthesizing the certain steroids described herein.

[0009] FIG. 2. shows a sequence for modifying the primary alcohol position of budesonide.

[0010] FIG. 3. shows a sequence for modifying the primary alcohol position of Flumethasone.

[0011] FIG. 4. shows a sequence for modifying the primary alcohol position of dexamethasone.

[0012] FIG. 5 shows a two–dimensional nuclear Overhauser effect (NOE) magnetic resonance spectrum (hereinafter "2D–NOESY") for compound 7-1*R* in Table 1.

[0013] FIG. 6 shows a 2D–NOESY for compound 7-1*S* in Table 1.

[0014] FIG. 7 shows a 2D–NOESY spectrum for 11-5*R* in Table 1.

[0015] FIG. 8 shows a 2D–NOESY spectrum for compound 11-5*S* in Table 1.



wherein x is an integer from 1 to 30; and n is an integer from 1 to 30;
or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.

39. Use of a compound of any of claims 1-28 or a compound of any one of claims 29-38 for treating a disease, disorder, or condition associated with glucocorticoid receptor signaling comprising administering to a patient having said disease, disorder, or condition.

40. The use of claim 39, wherein the disease, disorder, or condition, is an inflammatory disease, disorder, or condition.

41. The use of claim 40, wherein the compound is a compound of any one of claims 14-18.

42. The use of claim 41, wherein side effects associated with administration of the unconjugated steroid payload of said compound are reduced.

43. An *in vitro* method of delivering a compound of claim 1 to a cell comprising contacting said cell with a protein steroid conjugate of said compound, wherein said protein conjugate comprises an antibody or antigen binding fragment thereof that binds a surface antigen of said cell.

44. A linker-payload comprising the compound of any of claims 1-28 linked to a reactive group, optionally via a linker.

45. The linker-payload of claim 44 selected from the group consisting of:

